Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis
Ist Teil von
Journal of neurology, 2024-06, Vol.271 (6), p.3169-3185
Ort / Verlag
Berlin/Heidelberg: Springer Berlin Heidelberg
Erscheinungsjahr
2024
Quelle
SpringerLink
Beschreibungen/Notizen
Objective
To assess the effectiveness and tolerability of brivaracetam (BRV) in adults with epilepsy by specific comorbidities and epilepsy etiologies.
Methods
EXPERIENCE/EPD332 was a pooled analysis of individual patient records from several non-interventional studies of patients with epilepsy initiating BRV in clinical practice. Outcomes included ≥ 50% reduction from baseline in seizure frequency, seizure freedom (no seizures within prior 3 months), continuous seizure freedom (no seizures since baseline), BRV discontinuation, and treatment-emergent adverse events (TEAEs) at 3, 6, and 12 months. Analyses were performed for all adult patients (≥ 16 years of age) and stratified by comorbidity and by etiology at baseline (patients with cognitive/learning disability [CLD], psychiatric comorbidity, post-stroke epilepsy, brain tumor−related epilepsy [BTRE], and traumatic brain injury−related epilepsy [TBIE]).
Results
At 12 months, ≥ 50% seizure reduction was achieved in 35.6% (
n
= 264), 38.7% (
n
= 310), 41.7% (
n
= 24), 34.1% (
n
= 41), and 50.0% (
n
= 28) of patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, respectively; and continuous seizure freedom was achieved in 5.7% (
n
= 318), 13.7% (n = 424), 29.4% (n = 34), 11.4% (
n
= 44), and 13.8% (
n
= 29), respectively. During the study follow-up, in patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, 37.1% (
n
= 403), 30.7% (
n
= 605), 33.3% (
n
= 51), 39.7% (
n
= 68), and 27.1% (
n
= 49) of patients discontinued BRV, respectively; and TEAEs since prior visit at 12 months were reported in 11.3% (
n
= 283), 10.0% (
n
= 410), 16.7% (
n
= 36), 12.5% (
n
= 48), and 3.0% (
n
= 33), respectively.
Conclusions
BRV as prescribed in the real world is effective and well tolerated among patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE.